MarketCap
Mirum Pharmaceuticals MIRM
$ 89.7
0.38%
Facebook
X
Telegram
Mirum Pharmaceuticals Accounts Receivables | MIRM
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Mirum Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123 M | 78.3 M | 68 M | 24 M | 3.27 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 123 M | 3.27 M | 59.4 M |
Quarterly Accounts Receivables Mirum Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 145 M | 133 M | 107 M | 107 M | 95.9 M | 78.3 M | 68.5 M | 60.4 M | 55 M | 68 M | 47.8 M | 35.3 M | 24.7 M | 24 M | 16.3 M | - | 7.87 M | 3.27 M | 400 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 145 M | 400 K | 59.9 M |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AnaptysBio
ANAB
|
25.6 M | $ 51.0 | 1.83 % | $ 1.48 B |  USA |
 |
Clovis Oncology
CLVS
|
26.9 M | - | -7.23 % | $ 13 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
218 K | - | - | $ 401 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
908 M | $ 60.26 | 0.06 % | $ 11.6 B | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
97 K | - | - | $ 384 M |  Britain |
 |
Catalyst Biosciences
CBIO
|
31.1 M | $ 13.99 | 0.84 % | $ 1.25 B | USA |
 |
C4 Therapeutics
CCCC
|
2.4 M | $ 2.98 | 0.3 % | $ 247 M | USA |
 |
Codexis
CDXS
|
10 M | $ 1.32 | 1.09 % | $ 115 M | USA |
 |
Cerus Corporation
CERS
|
30.4 M | $ 2.62 | 0.38 % | $ 499 M | USA |
 |
G1 Therapeutics
GTHX
|
12.7 M | - | - | $ 370 M | USA |
 |
Coherus BioSciences
CHRS
|
17.8 M | $ 1.13 | 0.43 % | $ 132 M | USA |
 |
Celldex Therapeutics
CLDX
|
2.02 M | $ 31.1 | 1.16 % | $ 2.07 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
1 K | $ 4.25 | 3.16 % | $ 51.9 M |  Israel |
 |
AbbVie
ABBV
|
12.6 B | $ 264.34 | 0.09 % | $ 468 B | USA |
 |
Humanigen
HGEN
|
44 K | - | -81.12 % | $ 4.28 M | USA |
 |
Cocrystal Pharma
COCP
|
556 K | $ 1.17 | 1.74 % | $ 13.2 M | USA |
 |
AbCellera Biologics
ABCL
|
39.4 M | $ 12.7 | 0.4 % | $ 3.79 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
3 | $ 5.4 | 2.65 % | $ 286 M | USA |
 |
Collegium Pharmaceutical
COLL
|
211 M | $ 22.53 | 0.2 % | $ 713 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
59.8 M | $ 116.1 | 4.93 % | $ 12.1 B | USA |
 |
IGM Biosciences
IGMS
|
800 K | - | - | $ 76.9 M | USA |
 |
Cardiff Oncology
CRDF
|
182 K | $ 1.24 | 0.74 % | $ 82.9 M | USA |
 |
Karuna Therapeutics
KRTX
|
57 K | - | - | $ 12.2 B | USA |
 |
Curis
CRIS
|
3.35 M | $ 0.83 | 1.1 % | $ 10.9 M | USA |
 |
CorMedix
CRMD
|
171 M | $ 7.85 | 1.03 % | $ 565 K | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
592 K | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
25 M | $ 54.23 | 0.23 % | $ 4.88 B |  Schweiz |
 |
Champions Oncology
CSBR
|
13.2 M | $ 4.9 | 0.1 % | $ 67.8 M | USA |
 |
Chimerix
CMRX
|
57 K | - | - | $ 756 M | USA |
 |
Corvus Pharmaceuticals
CRVS
|
37 K | $ 11.62 | 8.21 % | $ 918 M | USA |
 |
Cue Biopharma
CUE
|
5.55 M | $ 31.41 | 1.45 % | $ 2.98 B | USA |
 |
CEL-SCI Corporation
CVM
|
54.9 K | $ 1.67 | 2.38 % | $ 13.4 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
1.45 M | $ 4.85 | 0.2 % | $ 929 M | Canada |
 |
Cytokinetics, Incorporated
CYTK
|
17.8 M | $ 64.66 | 0.17 % | $ 7.77 M | USA |
 |
Adagene
ADAG
|
3 M | $ 2.93 | 2.86 % | $ 173 M |  China |
 |
DiaMedica Therapeutics
DMAC
|
258 K | $ 7.94 | 1.4 % | $ 373 M | USA |